Posts Tagged

Press Release

Feb 2021

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Jan 2021

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target

BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Nov 2020

FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI

BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Sep 2020

BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial

NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.